Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
C. Desbans, C. Hilgendorf, M. Lutz, P. Bachellier, T. Zacharias, J. C. Weber, H. Dolgos, L. Richert & A.-L. Ungell. (2014) Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors. Xenobiotica 44:1, pages 17-27.
Read now
Read now
Karen Rowland Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2013) Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology 6:2, pages 143-157.
Read now
Read now
Articles from other publishers (44)
Doha Naga, Neil Parrott, Gerhard F. Ecker & Andrés Olivares-Morales. (2022) Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery. Molecular Pharmaceutics 19:7, pages 2203-2216.
Crossref
Crossref
Kentaro Ohta, Nobuko Matsushima, Hiromi Tanii, Herta Crauwels, Toshiyuki Kudo & Kiyomi Ito. (2021) Pharmacokinetics and safety of rilpivirine in healthy Japanese subjects and exploration of ethnic sensitivity of rilpivirine pharmacokinetics with physiologically based pharmacokinetic model approach. Drug Metabolism and Pharmacokinetics 41, pages 100422.
Crossref
Crossref
Nicola Melillo & Adam S. Darwich. (2021) A latent variable approach to account for correlated inputs in global sensitivity analysis. Journal of Pharmacokinetics and Pharmacodynamics 48:5, pages 671-686.
Crossref
Crossref
Shu-Hao Hsu, An-Chun Cheng, Tien-Yu Chang, Li-Heng Pao, Cheng-Huei Hsiong & Hong-Jaan Wang. (2021) Precisely adjusting the hepatic clearance of highly extracted drugs using the modified well-stirred model. Biomedicine & Pharmacotherapy 141, pages 111855.
Crossref
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
469
482
.
Takashi Ueno, Yukiko Miyajima, Ishani Landry, Bojan Lalovic & Edgar Schuck. (2021) Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors. CPT: Pharmacometrics & Systems Pharmacology 10:5, pages 455-466.
Crossref
Crossref
Jeffry Adiwidjaja, Alan V. Boddy & Andrew J. McLachlan. (2020) Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics. Frontiers in Pharmacology 10.
Crossref
Crossref
Yingying Guo, Aroonrut Lucksiri, Gemma L. Dickinson, Raj K. Vuppalanchi, Janna K. Hilligoss & Stephen D. Hall. (2019) Quantitative Prediction of CYP3A4‐ and CYP3A5‐Mediated Drug Interactions. Clinical Pharmacology & Therapeutics 107:1, pages 246-256.
Crossref
Crossref
Sheila Annie Peters & Hugues Dolgos. (2019) Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them. Clinical Pharmacokinetics 58:11, pages 1355-1371.
Crossref
Crossref
Felix Stader, Melissa A. Penny, Marco Siccardi & Catia Marzolini. (2019) A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab. CPT: Pharmacometrics & Systems Pharmacology.
Crossref
Crossref
Neha Maharao, Jurgen Venitz & Phillip M. Gerk. (2019) Use of generally recognized as safe or dietary compounds to inhibit buprenorphine metabolism: potential to improve buprenorphine oral bioavailability. Biopharmaceutics & Drug Disposition 40:1, pages 18-31.
Crossref
Crossref
Ken-ichi Umehara, Felix Huth, Christina S. Won, Tycho Heimbach & Handan He. (2018) Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates. Biopharmaceutics & Drug Disposition 39:3, pages 152-163.
Crossref
Crossref
Kenta Haraya, Motohiro Kato, Koji Chiba & Yuichi Sugiyama. (2017) Prediction of inter-individual variability on the pharmacokinetics of CYP2C8 substrates in human. Drug Metabolism and Pharmacokinetics 32:6, pages 277-285.
Crossref
Crossref
Helen Musther, Matthew D. Harwood, Jiansong Yang, David B. Turner, Amin Rostami-Hodjegan & Masoud Jamei. (2017) The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model. Journal of Pharmaceutical Sciences 106:9, pages 2826-2838.
Crossref
Crossref
Caroline L. Ring, Robert G. Pearce, R. Woodrow Setzer, Barbara A. Wetmore & John F. Wambaugh. (2017) Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability. Environment International 106, pages 105-118.
Crossref
Crossref
Wangda Zhou, Helen Humphries, Sibylle Neuhoff, Iain Gardner, Eric Masson, Nidal Al-Huniti & Diansong Zhou. (2017) Development of a physiologically based pharmacokinetic model to predict the effects of flavin-containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure. Biopharmaceutics & Drug Disposition 38:6, pages 389-393.
Crossref
Crossref
Rachel H. Rose, David B. Turner, Sibylle Neuhoff & Masoud Jamei. (2017) Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs. The AAPS Journal 19:4, pages 1205-1217.
Crossref
Crossref
In-Wha Kim & Jung Mi Oh. (2017) Deep learning: from chemoinformatics to precision medicine. Journal of Pharmaceutical Investigation 47:4, pages 317-323.
Crossref
Crossref
Nicole A. Kratochwil, Christophe Meille, Stephen Fowler, Florian Klammers, Aynur Ekiciler, Birgit Molitor, Sandrine Simon, Isabelle Walter, Claudia McGinnis, Johanna Walther, Brian Leonard, Miriam Triyatni, Hassan Javanbakht, Christoph Funk, Franz Schuler, Thierry Lavé & Neil J. Parrott. (2017) Metabolic Profiling of Human Long-Term Liver Models and Hepatic Clearance Predictions from In Vitro Data Using Nonlinear Mixed-Effects Modeling. The AAPS Journal 19:2, pages 534-550.
Crossref
Crossref
M. F. Rasool, F. Khalil & S. Laer. (2016) Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach. Drug Metabolism and Disposition 44:7, pages 1103-1115.
Crossref
Crossref
L. M. Almond, S. Mukadam, I. Gardner, K. Okialda, S. Wong, O. Hatley, S. Tay, K. Rowland-Yeo, M. Jamei, A. Rostami-Hodjegan & J. R. Kenny. (2016) Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model. Drug Metabolism and Disposition 44:6, pages 821-832.
Crossref
Crossref
Carrie C. Hoefer, Adolfo Quiñones-Lombraña, Rachael Hageman Blair & Javier G. Blanco. (2015) Role of DNA Methylation on the Expression of the Anthracycline Metabolizing Enzyme AKR7A2 in Human Heart. Cardiovascular Toxicology 16:2, pages 182-192.
Crossref
Crossref
J Snoeys, M Beumont, M Monshouwer & S Ouwerkerk-Mahadevan. (2016) Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach. Clinical Pharmacology & Therapeutics 99:2, pages 224-234.
Crossref
Crossref
Jennifer E. Sager, Jingjing Yu, Isabelle Ragueneau-Majlessi & Nina Isoherranen. (2015) Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification. Drug Metabolism and Disposition 43:11, pages 1823-1837.
Crossref
Crossref
Muhammad Fawad Rasool, Feras Khalil & Stephanie Läer. (2015) A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows. Clinical Pharmacokinetics 54:9, pages 943-962.
Crossref
Crossref
Aki T. Heikkinen, Floriane Lignet, Paul Cutler & Neil Parrott. (2015) The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. PROTEOMICS - Clinical Applications 9:7-8, pages 732-744.
Crossref
Crossref
Boyd Steere, Jessica A. Roseberry Baker, Stephen D. Hall & Yingying Guo. (2015) Prediction of In Vivo Clearance and Associated Variability of CYP2C19 Substrates by Genotypes in Populations Utilizing a Pharmacogenetics-Based Mechanistic Model. Drug Metabolism and Disposition 43:6, pages 870-883.
Crossref
Crossref
Aki T. Heikkinen, Arno Friedlein, Mariette Matondo, Oliver J. D. Hatley, Aleksanteri Petsalo, Risto Juvonen, Aleksandra Galetin, Amin Rostami-Hodjegan, Ruedi Aebersold, Jens Lamerz, Tom Dunkley, Paul Cutler & Neil Parrott. (2014) Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine. Pharmaceutical Research 32:1, pages 74-90.
Crossref
Crossref
Khaled Abduljalil, Theresa Cain, Helen Humphries & Amin Rostami-Hodjegan. (2014) Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations. Drug Metabolism and Disposition 42:9, pages 1478-1484.
Crossref
Crossref
Kati-Sisko Vellonen, Melina Malinen, Eliisa Mannermaa, Astrid Subrizi, Elisa Toropainen, Yan-Ru Lou, Heidi Kidron, Marjo Yliperttula & Arto Urtti. (2014) A critical assessment of in vitro tissue models for ADME and drug delivery. Journal of Controlled Release 190, pages 94-114.
Crossref
Crossref
Brahim Achour, Matthew R. Russell, Jill Barber & Amin Rostami-Hodjegan. (2014) Simultaneous Quantification of the Abundance of Several Cytochrome P450 and Uridine 5′-Diphospho-Glucuronosyltransferase Enzymes in Human Liver Microsomes Using Multiplexed Targeted Proteomics. Drug Metabolism and Disposition 42:4, pages 500-510.
Crossref
Crossref
Emile P. Chen, Guoying Tai & Harma Ellens. (2013) The Importance of Villous Physiology and Morphology in Mechanistic Physiologically-Based Pharmacokinetic Models. Pharmaceutical Research 31:2, pages 305-321.
Crossref
Crossref
Zoe E. Barter, Geoffrey T. Tucker & Karen Rowland-Yeo. (2013) Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 52:12, pages 1085-1100.
Crossref
Crossref
Patrick Poulin & Sami Haddad. (2013) Toward a new paradigm for the efficient in vitro–in vivo extrapolation of metabolic clearance in humans from hepatocyte data. Journal of Pharmaceutical Sciences 102:9, pages 3239-3251.
Crossref
Crossref
Neil Parrott, Dominik Hainzl, Daniela Alberati, Carsten Hofmann, Richard Robson, Bruno Boutouyrie & Meret Martin-Facklam. (2013) Physiologically Based Pharmacokinetic Modelling to Predict Single- and Multiple-Dose Human Pharmacokinetics of Bitopertin. Clinical Pharmacokinetics 52:8, pages 673-683.
Crossref
Crossref
Zheng Yang, Blisse Vakkalagadda, Guoxiang Shen, Christoph M. Ahlers, Teresa Has, Lisa J. Christopher, John F. Kurland, Vikram Roongta, Eric Masson & Steven Zhang. (2013) Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS‐690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically‐Based Pharmacokinetic Simulations. The Journal of Clinical Pharmacology 53:2, pages 217-227.
Crossref
Crossref
M. D. Harwood, S. Neuhoff, G. L. Carlson, G. Warhurst & A. Rostami‐Hodjegan. (2012)
Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic
in vitro–in vivo
extrapolation of oral drug absorption
. Biopharmaceutics & Drug Disposition 34:1, pages 2-28.
Crossref
Crossref
Aki T. Heikkinen, Guillaume Baneyx, Antonello Caruso & Neil Parrott. (2012) Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™. European Journal of Pharmaceutical Sciences 47:2, pages 375-386.
Crossref
Crossref
Sheila Annie Peters, Patricia E. Schroeder, Nagdeep Giri & Hugues Dolgos. (2012) Evaluation of the Use of Static and Dynamic Models to Predict Drug-Drug Interaction and Its Associated Variability: Impact on Drug Discovery and Early Development. Drug Metabolism and Disposition 40:8, pages 1495-1507.
Crossref
Crossref
Lian Zhou, Randy C. Dockens, Peggy Liu-Kreyche, Scott J. Grossman & Ramaswamy A. Iyer. (2012) In Vitro and In Vivo Metabolism and Pharmacokinetics of BMS-562086, a Potent and Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist. Drug Metabolism and Disposition 40:6, pages 1093-1103.
Crossref
Crossref
Guillaume Baneyx, Yumi Fukushima & Neil Parrott. (2012) Use of physiologically based pharmacokinetic modeling for assessment of drug–drug interactions. Future Medicinal Chemistry 4:5, pages 681-693.
Crossref
Crossref
Cyrus Ghobadi, Trevor N. Johnson, Mohsen Aarabi, Lisa M. Almond, Aurel Constant Allabi, Karen Rowland-Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2011) Application of a Systems Approach to the Bottom-Up Assessment of Pharmacokinetics in Obese Patients. Clinical Pharmacokinetics 50:12, pages 809-822.
Crossref
Crossref
H. T'jollyn, K. Boussery, R. J. Mortishire-Smith, K. Coe, B. De Boeck, J. F. Van Bocxlaer & G. Mannens. (2011) Evaluation of Three State-of-the-Art Metabolite Prediction Software Packages (Meteor, MetaSite, and StarDrop) through Independent and Synergistic Use. Drug Metabolism and Disposition 39:11, pages 2066-2075.
Crossref
Crossref
H. K. Crewe, Z. E. Barter, K. Rowland Yeo & A. Rostami‐Hodjegan. (2011) Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors. Biopharmaceutics & Drug Disposition 32:6, pages 303-318.
Crossref
Crossref